Focal adhesion kinase provides a collateral vulnerability that can be leveraged to improve mtorc1 inhibitor efficacy

HIGHLIGHTS

• who: Leslie Cuellar-Vite and collaborators from the Department of Pharmacology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA have published the Article: Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy, in the Journal: Cancers 2022, x of /2022/
• what: As an alternative approach to discovering mechanisms of resistance to mTORC1i, the authors focused on a breast cancer subtype (TNBC) where intrinsic in_vitro resistance is well-established. Immunological response is unlikely to play a role in the synergy between FAK and mTORC1i because the studies . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.